Neuland Q1 PAT up 10x to Rs 148 cr, revenue doubles; Rs 40 cr capex and Gland Pharma CDMO deal

Neuland Labs Q1 FY27 consolidated revenue from operations jumped to Rs 641.6 crores from Rs 292.8 crores YoY, a 119 percent rise. PAT surged to Rs 147.7 crores from Rs 13.9 crores, nearly 10 times growth. EPS stood at Rs 115.10 versus Rs 10.83. Board approved adding 18 KL capacity at Unit 1 Bonthapally for Rs 39.8 crores funded via internal accruals, to be completed in 6-7 months. Current capacity utilization is 91 percent. Also signed a long-term CDMO partnership with Gland Pharma for sterile API manufacturing, backed by a Rs 40 crore corporate guarantee.